Novartis has secured European Commission approval for Itvisma for the treatment of children aged two years and older, as well ...

AlzeCure Pharma has signed an out‑licensing and collaboration agreement with Danish biotech QuantumCell ApS, granting global ...

Applications have opened for the ninth cohort of KQ Labs, the national accelerator for data‑driven health start‑ups delivered ...

Asgard Therapeutics will present new preclinical data on its lead asset AT‑108 in an oral presentation at the ASGCT Annual Meeting, taking place from 11–15 May in Boston. AT‑108 is a first‑in‑class, ...

Agomab Therapeutics has announced the design of its phase 2b NOV‑ERA study of ontunisertib in fibrostenosing Crohn’s disease, ...

R1 Therapeutics has formed a scientific advisory board comprising seven internationally recognised nephrology experts as the ...

US study marks company’s second clinical trial of ovarian cancer therapy Theolytics has dosed the first patient in a phase 1 clinical trial investigating intraperitoneal administration of THEO‑260 for ...

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...

Clesrovimab is first monoclonal antibody offering a single fixed dose for infants The UK’s Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia ...

Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, for adults with systemic lupus erythematosus receiving standard therapy. The ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...